AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance
Fuels Ambition To Be Leading Heart Failure Firm
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.
